Ranbaxy seeks USFDA nod for withdrawing 28 drug applications

The older drugs belong to erstwhile Ranbaxy Labs and have not been marketed in the US since 2008

Drug major Sun Pharma on Tuesday said one of its subsidiaries has voluntarily requested the US health regulator to withdraw approval for 28 abbreviated new drug applications belonging to Ranbaxy Laboratories.

In a BSE filing, Sun Pharmaceutical Industries said: "One of the company's wholly-owned subsidiaries has voluntarily requested the US Food and Drugs Administration (FDA) to withdraw approval for 28 abbreviated new drug applications."

It further said: "These older drug products belong to erstwhile Ranbaxy Laboratories and are not being marketed in the US since 2008."

In April 2014, Sun Pharma had announced the acquisition of the troubled rival Ranbaxy in an all-stock transaction worth $4 billion.

 

Shares of Sun Pharma were trading 0.15 per cent lower at Rs 631.25 apiece on BSE.